

**AMENDMENTS TO THE CLAIMS**

1-7. (Canceled)

8. (Currently Amended) A peptide compound which selectively binds to the extracellular portion of human PSMA ~~The peptide compound of claim 28,~~ consisting of the amino acid sequence set forth as SEQ ID NO:1.

9-27. (Canceled)

28. (Currently Amended) A peptide compound which selectively binds to the extracellular portion of human PSMA and comprises at least 5 residues ~~in common with~~ of the consensus sequence QKHHNYL (SEQ ID NO:109), wherein the 5 residues are within a linear span of 7 amino acid residues.

29. (Currently Amended) The peptide of claim 28, wherein the peptide has at least 6 residues ~~in common with~~ of the consensus sequence QKHHNYL (SEQ ID NO:109), wherein the 6 residues are within a linear span of 7 amino acid residues.

30. (Previously Presented) The peptide of claim 28, wherein the peptide has the consensus sequence QKHHNYL (SEQ ID NO:109).

31. (Previously Presented) The peptide of claim 30, wherein the peptide is 9 amino acid residues in length.

32. (Previously Presented) The peptide of claim 28 or 31, wherein the peptide comprises a cysteine residue at the N and C terminus.

33. (Previously Presented) The peptide of claim 32, wherein the peptide is cyclic.

34. (Previously Presented) The peptide of claim 28, wherein the peptide comprises one or more amino acid analogues.